AI MARKET SCANNING

REGENXBIO Inc

📅 Next Catalyst: Nov 05, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Health Technology 🏭 Pharmaceuticals Major
AVG HISTORICAL GAP -1.09%
MAX GAP RECORD -11.02%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $RGNX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
+7.43%
May 13, 2026 Earnings Release 2026-05-13 (BEFORE OPEN)
-1.66%
Mar 05, 2026 Earnings Release 2026-03-05 (BEFORE OPEN)
-7.99%
Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN)
-1.81%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
-2.79%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
+0.00%
Mar 13, 2025 Earnings Release 2025-03-13 (AFTER CLOSE)
+7.94%

VOLATILITY & GAP BIAS

AVG GAP MOVE 5.6%
Bullish Gaps (5)
Bearish Gaps (9)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $RGNX

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-28 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 1431m +1.54%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗